Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label vemurafenib study in BRAF V600 mutation-positive cancers
2011-004426-10Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vemurafenib and cetuximab in Nonhematologic neoplasms and multiple myeloma (MM) (2 arms), sponsored by Roche. Primary endpoint: Response rate at Week 8. Started Jan 2012; status: completed.
02
Drugs
vemurafenibcetuximab
03
Conditions
Nonhematologic neoplasmsmultiple myeloma (MM)
Beyond the preview
Go deeper on 2011-004426-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004426-10.